2篇
您的检索式：作者名="Binshen Ouyang"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Etoposide,dexamethasone,and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma:A randomized phase III study显示文摘Methotrexate,etoposide,dexamethasone,and pegaspargase(MESA)with sandwiched radiotherapy is known to be effective for early-stage extranodal natural killer/T-cell lymphoma,nasal type(NKTCL).We explored the efficacy and safety of reduced-intensity,non-intravenous etoposide,dexamethasone,and pegaspargase(ESA)with sandwiched radiotherapy.This multicenter,randomized,phase III trial enrolled patients aged between 14 and 70 years with newly diagnosed early-stage nasal NKTCL from 27 centers in China.Patients were randomly assigned(1:1)to receive ESA(pegaspargase 2,500 IU/m^(2)intramuscularly on day 1,etoposide 200 mg orally,and dexamethasone 40 mg orally on days 2–4)or MESA(methotrexate 1 g/m^(2)intravenously on day 1,etoposide 200 mg orally,and dexamethasone 40 mg orally on days 2–4,and pegaspargase 2,500 IU/m^(2)intramuscularly on day 5)regimen(four cycles),combined with sandwiched radiotherapy. | Huijuan Zhong Shu Cheng Xi Zhang Bing Xu Jiayi Chen Xufeng Jiang Jie Xiong Yu Hu Guohui Cui Juying Wei Wenbin Qian Xiaobing Huang Ming Hou Feng Yan Xin Wang Yongping Song Jianda Hu Yuanhua Liu Xuejun Ma Fei Li Chongyang Wu Junmin Chen Li Yu Ou Bai Jingyan Xu Zunmin Zhu Li Liu Xin Zhou Li Huang Yin Tong Ting Niu Depei Wu Hao Zhang Chaofu Wang Binshen Ouyang Hongmei Yi Qi Song Gang Cai Biao Li Jia Liu Zhifeng Li Rong Xiao Luqun Wang Yujie Jiang Yanyan Liu Xiaoyun Zheng Pengpeng Xu Hengye Huang Li Wang Saijuan Chen Weili Zhao | 2023 | The Innovation2023，4，3： | 0 |
| 2 | Presence of multiple abnormal immunologic markers is an independent prognostic factor of diffuse large B-cell lymphoma显示文摘Autoimmune diseases (ADs) increase the risk of non-Hodgkin's lymphoma and contribute to poor prognosis of patients. However, the association between immunologic markers and clinical outcome has rarely been investigated. This study aims to analyze the prognostic value of pretreatment immunologic markers in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL). We retrospectively reviewed the data on 502 patients with DLBCL treated in our institution from January 2013 to March 2018. Survival functions were estimated using Kaplan Meier method and Cox regression model. The 3-year progression free survival (PFS) and overall survival (OS) rates were 70.2% and 80.9%, respectively, and the complete remission (CR) rate was 78.1%. Among the patients, those with multiple (≥3) abnormal immunologic markers had significantly shorter 3-year PFS (52.7% vs. 77.3%, P < 0.001) and OS (68.5% vs. 85.8%, P=0.001) than those without multiple abnormal immunologic markers.Multivariate analysis revealed that the presence of multiple abnormal immunologic markers and the elevated serum levels of lactate dehydrogenase were the independent adverse prognostic factors for PFS (P= 0.008, P < 0.001) and OS (P = 0.003, P < 0.001). Meanwhile, advanced Ann Arbor stage was an independent adverse prognostic factor for PFS (P= 0.001) and age > 60 years for OS (P= 0.014). In conclusion, the immunologic status was closely related to lymphoma progression, and this study provides new insights into the risk stratification of patients with DLBCL. | Yiwen Cao Zhenhua Liu Wen Wu Ying Qian Qin Shi Rong Shen Binshen Ouyang Pengpeng Xu Shu Cheng Jin Ye Yiming Lu Chaofu Wang Chengde Yang Li Wang Weili Zhao | 2019 | Frontiers of Medicine2019，13，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员